|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Vinita_Gupta
|
|
gptkbp:country
|
gptkb:India
|
|
gptkbp:director
|
gptkb:Nilesh_Gupta
|
|
gptkbp:focusArea
|
gptkb:CNS
gptkb:Pediatrics
Cardiology
Oncology
Minerals
Vitamins
Dermatology
Ophthalmology
Urology
Nephrology
Asthma
Gynecology
Nutritional supplements
Diabetology
Anti-Infectives
Gastro-Intestinal
|
|
gptkbp:foundedBy
|
gptkb:Desh_Bandhu_Gupta
|
|
gptkbp:foundedYear
|
1968
|
|
gptkbp:hasResearchCenter
|
gptkb:India
gptkb:United_States
|
|
gptkbp:headquartersLocation
|
gptkb:Mumbai
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lupin Group
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:ISIN
|
INE326A01037
|
|
gptkbp:manufacturingFacilities
|
gptkb:Australia
gptkb:Brazil
gptkb:Europe
gptkb:India
gptkb:Japan
gptkb:Mexico
gptkb:Philippines
gptkb:South_Africa
gptkb:United_States
|
|
gptkbp:market
|
Global
|
|
gptkbp:numberOfEmployees
|
20000+
|
|
gptkbp:products
|
Active pharmaceutical ingredients
Generic drugs
Branded formulations
|
|
gptkbp:publiclyTraded
|
Yes
|
|
gptkbp:revenue
|
INR 16,369 crore (FY 2022-23)
|
|
gptkbp:stockExchange
|
gptkb:NSE
BSE
|
|
gptkbp:stockSymbol
|
gptkb:LUPIN
|
|
gptkbp:subsidiary
|
gptkb:Lupin_Pharmaceuticals,_Inc.
|
|
gptkbp:website
|
https://www.lupin.com/
|
|
gptkbp:bfsParent
|
gptkb:Lupin_Limited
|
|
gptkbp:bfsLayer
|
7
|